PRESS ROOM

Cosmos Health Provides an Update on its Debt Balance and Proforma Interest Expense Reduced its debt by 78% from $21.2M in 2021 to $4.6M...

Cosmos Health Extends and Updates its Agreement to Acquire Cana Laboratories, a European Pharmaceutical Company Vertically Integrating...

Cosmos Health announced today that it has successfully cured the Nasdaq minimum bid price deficiency.

Cosmos Health announced today that CEO Greg Siokas has participated with $3 million in the approximately $32.5 million financing

Cosmos Health announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale